Evidence map›Paper›PMID 25040426›Full record

ArticleJournal of neurochemistry2014

Decreased astrocytic thrombospondin-1 secretion after chronic ammonia treatment reduces the level of synaptic proteins: in vitro and in vivo studies.

Arumugam R Jayakumar, Xiao Y Tong, Kevin M Curtis, Roberto Ruiz-Cordero, Nagarajarao Shamaladevi, Missa Abuzamel, Joshua Johnstone, Gabriel Gaidosh, Kakulavarapu V Rama Rao, Michael D Norenberg

Open access · bronzeAbstract read
In one paragraph

Article in Journal of neurochemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. The Role of Extracellular Matrix in Human Neurodegenerative Diseases.International journal of molecular sciences · 2022
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. 2021 ISHEN guidelines on animal models of hepatic encephalopathy.Liver international : official journal of the International Association for the Study of the Liver · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Arumugam R JayakumarLaboratory of Neuropathology, Veterans Affairs Medical Center, Miami, Florida, USA.
Xiao Y Tong
Kevin M Curtis
Roberto Ruiz-Cordero
Nagarajarao Shamaladevi
Missa Abuzamel
Joshua Johnstone
Gabriel Gaidosh
Kakulavarapu V Rama Rao
Michael D Norenberg
University of Miami · USVeterans Health Administration · USGeriatric Research Education and Clinical Center · US

Funding

The Permeability Transition in Hepatic EncephalopathyR01DK063311 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI NORENBERG, MICHAEL DAVID · 2003 to 2012
$1.8M
Osteogenic Maturation and Bone Repair Require 1,25- and 24,25-dihydroxyvitamin DF32AR062990 · NIAMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI CURTIS, KEVIN MATTHEW · 2012 to 2015
$172k
Astrocyte swelling/Brain Edema in Acute Liver Failure: Role of Endothelial CellsI01BX001459 · VA · MIAMI VA HEALTH CARE SYSTEM · PI NORENBERG, MICHAEL DAVID · 2013 to 2016
–
BLRD VA I01 BX001459NIAMS NIH HHS 7F32AR062990-02NIAMS NIH HHS F32 AR062990NIDDK NIH HHS DK063311NIDDK NIH HHS R01 DK063311
6 · The paper itself

Abstract

Chronic hepatic encephalopathy (CHE) is a major complication in patients with severe liver disease. Elevated blood and brain ammonia levels have been implicated in its pathogenesis, and astrocytes are the principal neural cells involved in this disorder. Since defective synthesis and release of astrocytic factors have been shown to impair synaptic integrity in other neurological conditions, we examined whether thrombospondin-1 (TSP-1), an astrocytic factor involved in the maintenance of synaptic integrity, is also altered in CHE. Cultured astrocytes were exposed to ammonia (NH₄Cl, 0.5-2.5 mM) for 1-10 days, and TSP-1 content was measured in cell extracts and culture media. Astrocytes exposed to ammonia exhibited a reduction in intra- and extracellular TSP-1 levels. Exposure of cultured neurons to conditioned media from ammonia-treated astrocytes showed a decrease in synaptophysin, PSD95, and synaptotagmin levels. Conditioned media from TSP-1 over-expressing astrocytes that were treated with ammonia, when added to cultured neurons, reversed the decline in synaptic proteins. Recombinant TSP-1 similarly reversed the decrease in synaptic proteins. Metformin, an agent known to increase TSP-1 synthesis in other cell types, also reversed the ammonia-induced TSP-1 reduction. Likewise, we found a significant decline in TSP-1 level in cortical astrocytes, as well as a reduction in synaptophysin content in vivo in a rat model of CHE. These findings suggest that TSP-1 may represent an important therapeutic target for CHE. Defective release of astrocytic factors may impair synaptic integrity in chronic hepatic encephalopathy. We found a reduction in the release of the astrocytic matricellular proteins thrombospondin-1 (TSP-1) in ammonia-treated astrocytes; such reduction was associated with a decrease in synaptic proteins caused by conditioned media from ammonia-treated astrocytes. Exposure of neurons to CM from ammonia-treated astrocytes, in which TSP-1 is over-expressed, reversed (by approx 75%) the reduction in synaptic proteins. NF-kB = nuclear factor kappa B; PSD95 = post-synaptic density protein 95; ONS = oxidative/nitrative stress.

Indexed as

AmmoniaAnimalsAntioxidantsAstrocytesFemaleHepatic EncephalopathyNerve Tissue ProteinsNF-kappa BPregnancyProto-Oncogene Proteins c-mycRatsSynapsesSynaptophysinThrombospondin 1TubulinAmmoniaAntioxidantsNerve Tissue ProteinsNF-kappa BProto-Oncogene Proteins c-mycSynaptophysinThrombospondin 1Tubulinammoniaastrocyteschronic hepatic encephalopathysynaptic proteinsthrombospondin-1

Identifiers

PMID25040426
PMCPMC4364553
OpenAlexW1969854592

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.